Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

13.75USD
6 Dec 2016
Change (% chg)

-- (--)
Prev Close
$13.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,635
52-wk High
$14.40
52-wk Low
$3.93

STML.OQ

Chart for STML.OQ

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: 0.18
Market Cap(Mil.): $263.43
Shares Outstanding(Mil.): 19.16
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 42.12 30.77
EPS (TTM): -2.17 -- --
ROI: -46.89 -0.81 15.23
ROE: -47.17 -1.52 16.56

BRIEF-Stemline Therapeutics reports Q3 financial results

* Stemline Therapeutics reports third quarter 2016 financial results and highlights recent regulatory and clinical progress

Nov 08 2016

BRIEF-Stemline announces seven presentations

* Stemline announces seven presentations, including oral presentation of updated SL-401 phase 2 BPDCN data, at upcoming ASH meeting Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Stemline Therapeutics expect to provide further updates around multiple SL-401

* Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For SL-401

Aug 23 2016

BRIEF-Stemline Therapeutics Q2 loss per share $0.52

* Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress

Aug 04 2016

Competitors

Earnings vs. Estimates